Abstract.A new BV R photometry of six prominent RS CVn stars: V711 Tau, UX Ari, IM Peg, II Peg, σ Gem and λ And, carried out during 1995-97, is presented. The new results reveal significant evolution in the shape as well as in the amplitude of light curves of these binaries. The traditional two-starspot model has been used to obtain the spot parameters from the observed light curves of the stars. Changes in spot area and their location on stellar surface can be noticed from extracted spot parameters. Some of these stars are found to have significant variation in (B − V ) and (V −R) colour indices. The (V − R) colour index variation found in IM Peg, II Peg and λ And have been used for determining starspot effective temperatures.
We have carried out BVR photometric and Ha spectroscopic observations of the star HD 61396 during 1998 March 20 to 1999 April 3. We have discovered regular optical photometric variability from this star, with an inferred period of 31X95^0X10 dY and an amplitude of ,0.18 mag. A possible period of 35X34^0X12 dY as determined with Hipparcos, cannot be completely ruled out, however. Modelling of its photometric light curve with two circular spots indicates that 5±21 per cent of the stellar surface is covered by dark starspots which are ,830 K cooler than the surrounding photosphere, and produce the observed rotational modulation of the optical flux. Optical spectroscopy reveals a variable Ha emission feature, indicating that it is an unusually active star.In addition, we have analysed archival X-ray data of HD 61396, obtained from serendipitous observations with the ROSAT X-ray observatory, and we also discuss the radio properties of this star, based on both published Green Bank and unpublished VLA observations. The strong photometric variability and Ha emission, the relatively hard X-ray spectrum, and the high X-ray and radio luminosities imply that HD 61396 is most likely to be a member of the RS CVn class of evolved active binary stars. Its X-ray and radio luminosities place it among the five most luminous active binaries detected so far.
'Cerebral'-refers to the brain. 'Palsy'-can mean weakness or paralysis or lack of muscle control. Therefore, cerebral palsy is a disorder of muscle control which results from some damage to part of the brain. Cerebral palsy (CP) is a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing foetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems. Approximately 80% to 90% of children with cerebral palsy have spastic cerebral palsy. The diagnosis of spasticity in children with CP requires a complete physical examination, with ancillary testing as needed. The aim of treatment is to encourage the child to learn to be as independent as possible. Some children who have mild cerebral palsy will not have any problems in achieving independence. For others, it will be a slow process. In some with severe difficulties, considerable assistance from others will always be needed. Specific treatment varies by individual and changes as needed if new issues develop. In general, treatment focuses on ways to maintain or improve a person's quality of life and overall health. The goal of management of cerebral palsy is not to cure or to achieve normalcy but to increase functionality, improve capabilities, and sustain health in terms of locomotion, cognitive development, social interaction, and independence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.